期刊文献+

乳腺导管原位癌超声图像特征及其与病理因素的关系 被引量:6

Ultrasound image features of ductal carcinoma in situ and their relations with pathological profiles
原文传递
导出
摘要 目的:观察乳腺导管原位癌(DCIS)超声图像特征,探讨其与Her-2蛋白表达等病理因素的关系。方法:回顾性分析66例乳腺导管原位癌的临床资料,分析患者超声图像的特征及肿块大小与钙化、浸润、Her-2表达的关系。结果:66例患者中,肿瘤>1 cm者42例,超声表现为形态不规则,边界不清的低回声区;肿瘤≤1 cm者24例,其中超声表现为导管扩张者7例,小结节9例,腺体增厚8例。超声检查肿块>1 cm的DCIS中,其钙化率低于≤1 cm者,但浸润率和Her-2阳性表达率均明显高于肿块≤1 cm者(均P<0.05)。超声检查诊断DCIS与病理结果的符合率为51%。结论:DCIS的超声表现具有特征性,肿块≤1 cm者常伴钙化,肿块>1 cm者提示预后不良。 Objective: To analyze the ultrasound image features of ductal carcinoma in situ(DCIS),and their relations with the pathological pro les.Methods: e clinical data of 66 DCIS patients were reviewed,and then the ultrasound image features of the patients and the relationships between the lesion size and calci cation,in ltration and Her-2 expression were analyzed.Results: Of the 66 patients,the lumps in 42 cases were larger than 1 cm,which presented as hypoechoicareas with irregular shape and unclear border in the ultrasound image;the lumps in 24 cases were less than or equal to 1 cm,which presented as duct dilation(7 cases),small nodule(9 cases),or gland thickening(8 cases).In DCIS larger than 1 cm,the calciication rate on ultrnsound examination was lower but iniltration and Her-2 positive expression rate were higher than those in DCIS less than or equal to 1 cm(all P0.05).he coincidence rate of ultrasound examination for diagnosis of DCIS with the inal pathological results was 51%.Conclusion: DCIS has its own characteristics in ultrasound images,and the lump less than or equal to 1 cm is oten accompanied with calciication,while the lump larger than 1 cm may predict a poor prognosis.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2013年第5期575-579,共5页 China Journal of General Surgery
关键词 乳腺肿瘤 诊断 导管 乳腺 原位 超声检查 Breast Neoplasms/diag Carcinoma Ductal Breast Carcinoma in Situ Ultrasonography
  • 相关文献

参考文献17

  • 1Sakorafas GH, Farley DR, Peros G. Recent advances and current controversies in the management of DCIS of the breast[J]. Cancer Treatment Rev, 2008, 34(6):483-497.
  • 2Tavassoli FA, Devilee P. World Health Organization Classification of Tumors:Pathology and Geneties of Tumors of The Breast and Female Genital Organs[M]. Lyon:LARC Press, 2003:10.
  • 3周辉红,徐秋华,燕山.乳腺导管内癌的超声研究[J].中国超声医学杂志,2008,24(4):367-369. 被引量:30
  • 4刘月洁,张颖,凌广花,李建国.彩色多普勒超声鉴别乳腺肿物良恶性的多因素分析[J].中国超声医学杂志,2008,24(2):119-122. 被引量:60
  • 5Rahber G, Sie Ac, Hansen GC, et al. Benign versus malignant solidbreast masses:US differentiation[J]. Rdiology, 1999, 213(3):889- 894.
  • 6严继萍,孙欣.彩色多普勒超声在乳腺肿块中的诊断价值[J].中国药物与临床,2002,2(5):336-337. 被引量:7
  • 7Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs masteclomy for ductal carcinoma in situ: French Survey experience[J]. Br J Cancer, 2009, 100(7): 1048- 1054.
  • 8Shin HJ, Kim HH, Kim SM, et al. Screening-detected and symptomatic ductd carcinoma in situ:differences in the sonographic and pathologic features[J]. A JR Am J Roentgenol, 2008, 190(2):516-525.
  • 9Beverly E, Hashimoto. Sonography of ductal carcinoma in Situ[J]. Uhrasound Clin, 2006, 1(4):631-643.
  • 10刘鹏,杨德启,乔新民,曹迎明,佟富中,周波,刘宏军.乳腺钼靶X线摄影和超声诊断乳腺导管内癌的对照研究[J].中国医学影像学杂志,2004,12(5):358-360. 被引量:37

二级参考文献59

共引文献159

同被引文献87

  • 1步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 2Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalizedmedicine[J]. Oncologist,2009,14(4): 320-368.
  • 3Shi YX, Tan YT, Yuan ZY, et al. Comparison of overall survival between the early use and delayed use of trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer[J]. Med Oncol,2012, 29(1) :39-47.
  • 4Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamidetherapy in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubiein (HERCULES) trial[J]. J Clin Oncol,2010,28(9) :1473-1480.
  • 5Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positlve locally advanced breast cancer (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010,375 (9712) : 377-384.
  • 6Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer[J]. Breast Cancer Res Treat, 2012,131(2) :371-383.
  • 7Warszawski A,Rottinger EM,Vogel R,et al.20 MHz ultrasonic imaging for quantitative assessment and documentation of early and late postradiation skin reactions in breast cancer patients[J].Radiother Oncol,1998,47(3):241-247.
  • 8Le Floch O,Gonzague L,Feil-Bastid C,et al.Factors influencing long term modification of the irradiated skin thickness in patients conservatively treated for breast carcinoma [J].Radiother Oncol,1998,48(suppl 1):S108.
  • 9Fisher B,Anderson S,Bryant J,et al.Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer[J].N EngL J Med,2002,347(16):1233-1241.
  • 10Wratten CR,OBrien PC,Hamilton CS,et al.Breast edema in patients undergoing breast-conserving treatment for breast cancer:Assessment via high frequency ultrasound[J].Breast J,2007,13(3);266-273.

引证文献6

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部